News

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen – Nasdaq


Fairfield Current

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen
Nasdaq
“Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy,” commented Dr. Steven C. Quay, CEO and President. “We anticipate retaining a
Maxim Stays Bullish on Atossa (ATOS) Stock Following Preliminary Phase 1 ResultsSmarter Analyst

all 17 news articles »


Source link